Patent intelligence · EP
EP 4210672
HYALURONSÄURE ODER SALZ DAVON ZUR INHALATION ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN UND INHALATORVORRICHTUNG DAMIT
HYALURONSÄURE ODER SALZ DAVON ZUR INHALATION ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN UND INHALATORVORRICHTUNG DAMIT
Patent details — EP 4210672
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Jul 19, 2023
- Expiration
- Jul 14, 2043
- Applicant
- ALFASIGMA SPA [IT]
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 00 A I, A61K 45/ 06 A I, A61K 47/ 26 A I
Quick answer
EP 4210672 (HYALURONSÄURE ODER SALZ DAVON ZUR INHALATION ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN UND INHALATORVORRICHTUNG DAMIT) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Jul 19, 2023. Expires Jul 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALFASIGMA SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 31/ 00 A I, A61K 45/ 06 A I, A61K 47/ 26 A I, A61K/3100, A61K/31728
More from ALFASIGMA SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2026027669
BIOMARQUEURS POUR DÉTERMINER LE TRAITEMENT DE LA RECTOCOLITE HÉMORRAGIQUE AVEC DU FILGOTINIB
granted -
IT 202300014295
COMPOSIZIONI ORODISPERSIBILI COMPRENDENTI BETAMETASONE FOSFATO
granted -
IT 202300012522
FLUOROMETIL-CARNITINA PER USO COME INIBITORE DI COLINA TRIMETILAMMINA (TMA) LIASI.
granted -
AU 2023257308
USES OF FARNESOID X RECEPTOR AGONISTS
granted -
IT 202300006237
COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.
granted -
IT 202300001434
PRODOTTO DI FERMENTAZIONE PER USO NEL TRATTAMENTO DI PATOLOGIE ASSOCIATE ALLA SINDROME METABOLICA E STEATOSI EPATICA.
granted -
CA 3263063
VELUSETRAG DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA PSEUDO-OBSTRUCTION INTESTINALE CHRONIQUE (POIC)
granted -
IT 202200013882
PRODOTTO DI FERMENTAZIONE PER IL TRATTAMENTO DI MALATTIE INFIAMMATORIE.
granted
Frequently asked questions
What is US patent 4210672?
EP 4210672 (HYALURONSÄURE ODER SALZ DAVON ZUR INHALATION ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN UND INHALATORVORRICHTUNG DAMIT) is held by ALFASIGMA SPA [IT]. Status: granted. Granted Jul 19, 2023. Expires Jul 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4210672?
ALFASIGMA SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 4210672 expire?
Our index shows an expiration date of Jul 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.